<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00583037</url>
  </required_header>
  <id_info>
    <org_study_id>05-242</org_study_id>
    <nct_id>NCT00583037</nct_id>
  </id_info>
  <brief_title>24-Hour NAVA Ventilation in Acute Respiratory Failure</brief_title>
  <official_title>FEASIBILITY OF 24 Hrs VENTILATION WITH NEURALLY ADJUSTED VENTILATORY ASSIST (NAVA) IN PATIENTS WITH ACUTE RESPIRATORY FAILURE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Unity Health Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neurally Adjusted Ventilatory Assist (NAVA) is a new mode of mechanical ventilation that is&#xD;
      controlled by the electrical activity of the diaphragm (EAdi). The EAdi is a signal that&#xD;
      represents the patient's breathing effort, and hence with NAVA, the assist being delivered is&#xD;
      synchronized and proportional to the demands of the patient. This is a prospective&#xD;
      physiological study of the feasibility of NAVA ventilation over 24 hours. The aim is to&#xD;
      demonstrate that NAVA can maintain spontaneous breathing and unload the respiratory muscles&#xD;
      during both sleep and wake cycles over a 24 hour period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, studies using NAVA technology have been limited to short term evaluations (under 3&#xD;
      hours). No serious adverse events have been observed in patients enrolled in our 3-hour study&#xD;
      of NAVA in patients with acute lung injury. All 15 patients successfully tolerated the period&#xD;
      of ventilation (i.e. there were no dropouts) with NAVA and the stability of the blood gas&#xD;
      parameters over time reveals the efficiency of this new mode of ventilation in regards to&#xD;
      oxygenation.&#xD;
&#xD;
      A longer study may help to evaluate patient tolerance of NAVA and stability over time. A&#xD;
      longer study will also demonstrate the feasibility of NAVA to adapt to changes in respiratory&#xD;
      drive, changes in patient status, and the interventions of health care providers. A longer&#xD;
      time frame should help us understand the parameters for titration of NAVA settings over time&#xD;
      and establish some indications/limits for the future use of this promising technique. This&#xD;
      intermediate study will generate the data necessary for the development of additional&#xD;
      protocols to refine NAVA application and to compare NAVA to other assist modes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of NAVA as assessed by: • Assessment of FiO2 changes • Assessment of the NAVA catheter function: o Stability of the EAdi signal from NAVA catheter o Requirements for NAVA catheter position change • Reasons for ventilator alarms</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient tolerance of NAVA as assessed by: • Changes in SAS scoring and sedation requirement • Changes in vital signs (HR/BP) and vasopressors requirements • Changes in oxygenation/ventilation</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Respiration, Artificial</condition>
  <condition>Respiratory Insufficiency</condition>
  <arm_group>
    <arm_group_label>NAVA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implementation of NAVA for 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neurally Adjusted Ventilatory Assist (NAVA)</intervention_name>
    <description>Mechanical ventilation controlled by diaphragm electrical activity</description>
    <arm_group_label>NAVA</arm_group_label>
    <other_name>Servo i Ventilator System- NAVA Catheters (6671277, 6671280, 6671282, 6671287, 6671290)</other_name>
    <other_name>Servo i Ventilator System- NAVA HW option (6671957)</other_name>
    <other_name>Servo i Ventilator System- NAVA SW option (6671965)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients admitted to the ICU will be screened on a daily basis for the presence of the&#xD;
             following characteristics:&#xD;
&#xD;
          -  Adult (&gt;18 years old) intubated and mechanically ventilated patients with evidence of&#xD;
             spontaneous breathing defined as:&#xD;
&#xD;
               1. Patient is on pressure support ventilation OR&#xD;
&#xD;
               2. Patient is on pressure control ventilation with the ability to trigger 50% of the&#xD;
                  breaths.&#xD;
&#xD;
          -  Sedation Agitation Score (SAS) score greater than or equal to 2&#xD;
&#xD;
          -  Presence of an arterial line&#xD;
&#xD;
          -  Patients meeting these criteria will be considered eligible for recruitment into the&#xD;
             study&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          -  Next of kin unavailable&#xD;
&#xD;
          -  Patient/next of kin refuses informed consent.&#xD;
&#xD;
          -  Attending physician refuses to allow enrollment&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
        Exclusion Criteria Related to the Technique:&#xD;
&#xD;
          -  Any contraindication to insertion of a nasogastric tube including, but not limited to:&#xD;
             severe oropharyngeal malformation or bleeding, esophageal varices, tumor, infection,&#xD;
             stenosis, or rupture&#xD;
&#xD;
          -  Hemophilia or other severe bleeding disorder&#xD;
&#xD;
          -  Presence or suspicion of central/brain stem neurologic disorder/severe neuromuscular&#xD;
             disease&#xD;
&#xD;
          -  Treatment with neuromuscular blockers&#xD;
&#xD;
          -  History of heart and/or lung transplantation&#xD;
&#xD;
        Exclusion Criteria Related to the Clinical Stability of the Patient:&#xD;
&#xD;
          -  Mean arterial blood pressure &lt; 60 mm Hg with or without vasopressors or inotropes&#xD;
&#xD;
          -  Any contraindication to reducing sedation to obtain a targeted SAS score of 3 (e.g.&#xD;
             anticipated hemodynamic instability after reduction of sedation)&#xD;
&#xD;
          -  Patients with evidence of any of the above exclusions will not be eligible for&#xD;
             enrollment in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice Brunet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christer Sinderby, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St-Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Sinderby C, Navalesi P, Beck J, Skrobik Y, Comtois N, Friberg S, Gottfried SB, Lindström L. Neural control of mechanical ventilation in respiratory failure. Nat Med. 1999 Dec;5(12):1433-6. Review.</citation>
    <PMID>10581089</PMID>
  </reference>
  <reference>
    <citation>Sinderby C. Ventilatory assist driven by patient demand. Am J Respir Crit Care Med. 2003 Oct 1;168(7):729-30.</citation>
    <PMID>14522808</PMID>
  </reference>
  <reference>
    <citation>Beck J, Brander L, Slutsky AS, Reilly MC, Dunn MS, Sinderby C. Non-invasive neurally adjusted ventilatory assist in rabbits with acute lung injury. Intensive Care Med. 2008 Feb;34(2):316-23. Epub 2007 Oct 25.</citation>
    <PMID>17960364</PMID>
  </reference>
  <reference>
    <citation>Beck J, Campoccia F, Allo JC, Brander L, Brunet F, Slutsky AS, Sinderby C. Improved synchrony and respiratory unloading by neurally adjusted ventilatory assist (NAVA) in lung-injured rabbits. Pediatr Res. 2007 Mar;61(3):289-94.</citation>
    <PMID>17314685</PMID>
  </reference>
  <reference>
    <citation>Allo JC, Beck JC, Brander L, Brunet F, Slutsky AS, Sinderby CA. Influence of neurally adjusted ventilatory assist and positive end-expiratory pressure on breathing pattern in rabbits with acute lung injury. Crit Care Med. 2006 Dec;34(12):2997-3004.</citation>
    <PMID>16957635</PMID>
  </reference>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2007</study_first_posted>
  <last_update_submitted>May 29, 2009</last_update_submitted>
  <last_update_submitted_qc>May 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Fabrice Brunet</name_title>
    <organization>St. Michael's Hospital</organization>
  </responsible_party>
  <keyword>Neurally Adjusted Ventilatory Assist</keyword>
  <keyword>Sleep quality</keyword>
  <keyword>Adult</keyword>
  <keyword>Critical Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

